Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Presse Med ; 42(5): e145-52, 2013 May.
Artigo em Francês | MEDLINE | ID: mdl-23433913

RESUMO

UNLABELLED: In France, patients over 50 years represent more than 23.6% of all registered cases in the French Hospital Database for HIV (FHDH), and 18% of newly HIV-diagnosed patients. OBJECTIVE: To describe the long-term evolution after 4 years of a cohort of HIV infected patients older than 60 years recruited in COREVIH Île-de-France Ouest. RESULTS: One hundred and forty-nine participants, 115 men (77%) and 34 women (23%), were included in the cohort analysis in 2004, and baseline characteristics were: median age 65.4 years (60.3-86.3), CDC stage C: 36%, HBV and HCV co-infections: four (2.7%) and eight (5.4%) patients, median time from first HIV infection diagnosis: 8.5 years (0.25-19.5), ongoing HAART regimen: 88%, median duration of ARV treatment: 7.5 years (0.2-15.5), baseline CD4 cells count: 372/mm(3) (18-1860), HIV viral load less than 200 c/ml: 104 (70%). After a 4-year follow-up, 111 patients were alive, all but one treated with HAART, 17/149 (11.5%) were lost for follow-up, and 21/149 were deceased (14%). Causes of death were acute cardiovascular disease (4/21), neoplasia (11/21), neurological disease 1/21, end stage liver disease 3/21, unknown 2/21. The prevalence of co-morbidities after 4 years of follow-up were: arterial hypertension 40/111 (36%), hypercholesterolemia 48/111 (43%), diabetes 23/111 (21%), kidney disease with renal insufficiency (creatinine clairance<60 ml/min): 36/111 (32%). At the end of follow-up, median CD4 cells count was 494/mm(3), and viral load was undetectable less than 200 c/ml in 107/111 patients (96%). No new opportunistic infection occurred during the 4-year follow-up, but 24 patients had a new diagnosis of neoplasia (incidence 40/1000 person-year). Cancer was the cause of death in 11/24. CONCLUSION: Clinical and immunological improvement was continuous under HAART in these aged HIV infected patients, but co-morbidities are frequently observed in this population, with high incidence of cardiovascular disease and neoplasia, and related mortality. A multidisciplinary approach, with preventive consultations, oncology and cardiovascular screening, as done in geriatrics, is warranted in the aging HIV population.


Assuntos
Envelhecimento/imunologia , Infecções por HIV/epidemiologia , Idoso , Idoso de 80 Anos ou mais , Fármacos Anti-HIV/uso terapêutico , Contagem de Linfócito CD4 , Doenças Cardiovasculares/epidemiologia , Causas de Morte , Comorbidade , Progressão da Doença , Suscetibilidade a Doenças , Feminino , Seguimentos , Infecções por HIV/tratamento farmacológico , Infecções por HIV/metabolismo , Hepatite Viral Humana/epidemiologia , Humanos , Hospedeiro Imunocomprometido , Masculino , Doenças Metabólicas/epidemiologia , Pessoa de Meia-Idade , Neoplasias/epidemiologia , Paris/epidemiologia , Carga Viral
2.
Int J Infect Dis ; 14 Suppl 3: e333-4, 2010 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-20579914

RESUMO

A 56-year-old woman with ankylosing spondylitis, treated for 3 months with infliximab, developed miliary tuberculosis with mediastinal lymphadenopathies and brain and splenic lesions. After initial improvement under anti-tuberculous therapy, she suffered an unexpectedly prolonged paradoxical worsening with several episodes of lymphadenopathy, including life-threatening ones, over a period of more than 14 months of follow-up. The outcome was favorable as a result of corticosteroid and surgical treatments. This phenomenon reflects a paradoxical reaction precipitated by infliximab withdrawal.


Assuntos
Anticorpos Monoclonais/efeitos adversos , Espondilite Anquilosante/terapia , Tuberculose Miliar/etiologia , Tuberculose Miliar/terapia , Corticosteroides/uso terapêutico , Antituberculosos/efeitos adversos , Antituberculosos/uso terapêutico , Feminino , Humanos , Infliximab , Doenças Linfáticas/etiologia , Doenças Linfáticas/cirurgia , Doenças Linfáticas/terapia , Doenças do Mediastino/etiologia , Doenças do Mediastino/terapia , Pessoa de Meia-Idade , Infecções Oportunistas/etiologia , Infecções Oportunistas/terapia , Recidiva , Fator de Necrose Tumoral alfa/antagonistas & inibidores
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA